OverviewSuggest Edit
DiaCarta provides precise cancer molecular tests including NRAS, EGFR and KRAS mutation test kits, PCR ready lysis kit, HPV E6/E7 mRNA test kits for cervical and head-neck cancer, cancer biomarker gene expression detection kits and superfast master mix.
DiaCarta supplies precise molecular diagnostic cancer assays that enable the most sensitive, reliable, and accurate detection of cancer biomarkers directly from a patient sample, including QClamp gene mutation tests, SuperbDNA gene expression assays, and QZol, the only PCR ready lysate solution . DiaCarta's NRAS, EGFR, and KRAS tests are highly sensitive and able to detect a broad set of mutations and are being used by hospitals and cancer clinical laboratories for the treatment of patients and by biotechnology and pharmaceutical companies for clinical research. ... Show more
| Type | Private | |
| HQ | Richmond, US | Map |
| Website | diacarta.com |
Latest Updates
| Employees (est.) (Feb 2019) | 40 | (+6%) |
Key People/Management at DiaCarta
DiaCarta Office Locations
DiaCarta has an office in Richmond
Richmond, US (HQ)
2600 Hilltop Dr
Report incorrect company information
DiaCarta Financials and Metrics
Summary Metrics
DiaCarta total Funding | $8 m |
DiaCarta latest funding size | $8 m |
Time since last funding | 4 years ago |
DiaCarta investors | BioVeda China Fund |
DiaCarta's latest funding round in January 2015 was reported to be $8 m. In total, DiaCarta has raised $8 m
Report incorrect company information
DiaCarta Online and Social Media Presence
54 Twitter followers
DiaCarta has 54 Twitter Followers. The number of followers has increased 6.6% month over month and increased 13.2% quarter over quarter
Report incorrect company information
DiaCarta Blogs
January 31, 2019
cfDNA Quantitation for Research and Clinical Applications
Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standa…
January 17, 2019
CIO Bulletin Announces DiaCarta Inc. As One of the 30 Fastest Growing Companies of 2018
DiaCarta announced that CIO Bulletin has named it among the 30 Fastest Growing Companies of 2018. The positioning is based on DiaCarta’s revenue growth, financial status, openness to innovation, global collaboration and partnership, flagship products launching, regulatory progress and ability to for…
November 15, 2018
Confirmation of NGS for False-negative Variants Using XNA Technology
Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standa…
DiaCarta Company Life and Culture
Report incorrect company information
DiaCarta Frequently Asked Questions
Who are DiaCarta key executives?
DiaCarta's key executives are Aiguo Zhang and Paul Okunieff.
How many employees does DiaCarta have?
DiaCarta has 40 employees.
Who are DiaCarta competitors?
Competitors of DiaCarta include Exco InTouch, Inventiva and Orbit Discovery.
Where is DiaCarta headquarters?
DiaCarta headquarters is located at 2600 Hilltop Dr, Richmond.
Where are DiaCarta offices?
DiaCarta has an office in Richmond.
How many offices does DiaCarta have?
DiaCarta has 1 office.